$12.93
Today
as of Aug 5, 16:52 ET
Last 30 days
Recent Press Releases & News
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer
Overview
52-week range
$7.23
$15
74% of range
Avg surprise (last 3)
+1.9%
Avg reaction (last 2)
-0.5%
50% positive
Latest IV / EM
112%
EM ±18.8% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 4, 2026 | Mar/2026 | $-0.34 | $-0.31 | -9.7% | +19.1% | -1.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.33 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.47 | $-0.46 | -2.2% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $-0.42 | $-0.51 | +17.6% | — | +0.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.49 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.45 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.37 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.44 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.50 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.36 | -$0.47 | +23.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-40M | — | $-37M | $-39M | $-33M | — | $-38M | $-36M |
| Net income | $-36M | — | $-33M | $-36M | $-30M | — | $-35M | $-32M |
| EPS (diluted) | $-0.34 | — | $-0.33 | $-0.47 | $-0.42 | — | $-0.49 | $-0.45 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $56M | $46M | $50M | $76M | $49M | $59M | $44M | $50M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $290M | $288M | $296M | $291M | $211M | $262M | $279M | $295M |
| Total assets | $437M | $409M | $431M | $347M | $243M | $274M | $302M | $329M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $21M | $25M | $24M | $23M | $23M | $31M | $28M | $27M |
| Total equity | $416M | $384M | $407M | $324M | $220M | $243M | $274M | $302M |